Skip to main content
Caplight Logo









Prompt Diagnostics

Prompt Diagnostics

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://prompt-dx.com/

Last Round

Grant

Oct 22, 2025

Total Funding Raised

$2.35M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Prompt Diagnostics is a biotechnology company that develops portable, rapid PCR-based diagnostic platforms for point-of-care infectious disease testing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

point-of-care testingPOCTrapid PCRmolecular diagnosticsmicrofluidic cartridgesdiagnostic instrumentsample-to-answerlab-on-a-chipmagnetofluidicsassay designrapid testingclinical diagnosticsportable diagnosticsmedical device startupbiotech hardware

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Prompt Diagnostics Comparables

Compare Prompt Diagnostics with similar companies based on industry and business-model similarity.

Prompt Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novel Microdevices
89%
QuantuMDx
83%
Fuse Diagnostics
82%

Prompt Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 22, 2025
GrantJun 27, 2024
AcceleratorMar 20, 2023
AcceleratorFeb 2, 2022
GrantSep 30, 2021

Prompt Diagnostics Investors

Notable investors and investment history

Prompt Diagnostics investors
InvestorRounds
CARB-XGrant
LifeBridge HealthAccelerator
NIH RADxGrant
Bill & Melinda Gates FoundationGrant
NucleateAccelerator
National Science FoundationAccelerator, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Monthly visitors increased 34% MoM, from 1.3K to 1.8K.

  • Oct 22, 2025

    $1.25M grant awarded by the National Science Foundation.

Prompt Diagnostics Filings

Explore SEC and related filing metadata, where available.

Prompt Diagnostics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Prompt Diagnostics's valuation, stock price, and market status.

Is Prompt a public or private company?

Prompt is a private company.

What is the current stock price of Prompt?

Prompt is a private company with no public stock price. No recent secondary market data is available.

How much is Prompt worth (valuation)?

Valuation information for Prompt is not publicly available.

Can I buy Prompt stock?

Prompt shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Prompt's last funding round?

Prompt's most recent funding round was Grant on June 15, 2025.

Who are the main investors in Prompt?

Key investors in Prompt include CARB-X, LifeBridge Health, NIH RADx, National Science Foundation.

Will Prompt IPO soon?

No public IPO plans have been announced for Prompt.

How can I track Prompt secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Prompt's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range7
Year Founded2020
Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?